• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    10 Health Care Stocks Whale Activity In Today's Session

    7/10/24 1:35:24 PM ET
    $ABBV
    $AMGN
    $ANNX
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ABBV alert in real time by email

    This whale alert can help traders discover the next big trading opportunities.

    Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.

    Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels.

    Below are some instances of options activity happening in the Health Care sector:

    Symbol PUT/CALL Trade Type Sentiment Exp. Date Strike Price Total Trade Price Open Interest Volume
    AMGN CALL SWEEP BEARISH 07/19/24 $320.00 $27.4K 2.5K 277
    LLY CALL TRADE BEARISH 08/16/24 $930.00 $26.5K 433 140
    TVTX PUT TRADE BULLISH 12/19/25 $17.50 $25.2K 0 60
    ABBV CALL TRADE BEARISH 01/17/25 $125.00 $42.9K 426 30
    ASRT PUT TRADE BULLISH 01/17/25 $3.00 $68.8K 42 25
    HIMS CALL SWEEP BEARISH 01/17/25 $20.00 $72.0K 12.0K 19
    CVS CALL SWEEP BEARISH 10/18/24 $52.50 $98.4K 359 2
    BMY PUT TRADE BULLISH 05/16/25 $33.00 $194.2K 274 0
    ANNX CALL TRADE BULLISH 07/19/24 $2.50 $37.5K 451 0
    BAX CALL TRADE BULLISH 08/23/24 $36.00 $94.7K 0 0

    Explanation

    These itemized elaborations have been created using the accompanying table.

    • For AMGN (NASDAQ:AMGN), we notice a call option sweep that happens to be bearish, expiring in 9 day(s) on July 19, 2024. This event was a transfer of 53 contract(s) at a $320.00 strike. This particular call needed to be split into 7 different trades to become filled. The total cost received by the writing party (or parties) was $27.4K, with a price of $516.0 per contract. There were 2586 open contracts at this strike prior to today, and today 277 contract(s) were bought and sold.

    • Regarding LLY (NYSE:LLY), we observe a call option trade with bearish sentiment. It expires in 37 day(s) on August 16, 2024. Parties traded 6 contract(s) at a $930.00 strike. The total cost received by the writing party (or parties) was $26.5K, with a price of $4418.0 per contract. There were 433 open contracts at this strike prior to today, and today 140 contract(s) were bought and sold.

    • For TVTX (NASDAQ:TVTX), we notice a put option trade that happens to be bullish, expiring in 527 day(s) on December 19, 2025. This event was a transfer of 30 contract(s) at a $17.50 strike. The total cost received by the writing party (or parties) was $25.2K, with a price of $840.0 per contract. There were 0 open contracts at this strike prior to today, and today 60 contract(s) were bought and sold.

    • For ABBV (NYSE:ABBV), we notice a call option trade that happens to be bearish, expiring in 191 day(s) on January 17, 2025. This event was a transfer of 10 contract(s) at a $125.00 strike. The total cost received by the writing party (or parties) was $42.9K, with a price of $4290.0 per contract. There were 426 open contracts at this strike prior to today, and today 30 contract(s) were bought and sold.

    • For ASRT (NASDAQ:ASRT), we notice a put option trade that happens to be bullish, expiring in 191 day(s) on January 17, 2025. This event was a transfer of 475 contract(s) at a $3.00 strike. The total cost received by the writing party (or parties) was $68.8K, with a price of $145.0 per contract. There were 42 open contracts at this strike prior to today, and today 25 contract(s) were bought and sold.

    • Regarding HIMS (NYSE:HIMS), we observe a call option sweep with bearish sentiment. It expires in 191 day(s) on January 17, 2025. Parties traded 150 contract(s) at a $20.00 strike. This particular call needed to be split into 20 different trades to become filled. The total cost received by the writing party (or parties) was $72.0K, with a price of $480.0 per contract. There were 12074 open contracts at this strike prior to today, and today 19 contract(s) were bought and sold.

    • Regarding CVS (NYSE:CVS), we observe a call option sweep with bearish sentiment. It expires in 100 day(s) on October 18, 2024. Parties traded 155 contract(s) at a $52.50 strike. This particular call needed to be split into 17 different trades to become filled. The total cost received by the writing party (or parties) was $98.4K, with a price of $635.0 per contract. There were 359 open contracts at this strike prior to today, and today 2 contract(s) were bought and sold.

    • Regarding BMY (NYSE:BMY), we observe a put option trade with bullish sentiment. It expires in 310 day(s) on May 16, 2025. Parties traded 1750 contract(s) at a $33.00 strike. The total cost received by the writing party (or parties) was $194.2K, with a price of $111.0 per contract. There were 274 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold.

    • For ANNX (NASDAQ:ANNX), we notice a call option trade that happens to be bullish, expiring in 9 day(s) on July 19, 2024. This event was a transfer of 150 contract(s) at a $2.50 strike. The total cost received by the writing party (or parties) was $37.5K, with a price of $250.0 per contract. There were 451 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold.

    • For BAX (NYSE:BAX), we notice a call option trade that happens to be bullish, expiring in 44 day(s) on August 23, 2024. This event was a transfer of 1298 contract(s) at a $36.00 strike. The total cost received by the writing party (or parties) was $94.7K, with a price of $73.0 per contract. There were 0 open contracts at this strike prior to today, and today 0 contract(s) were bought and sold.

    Options Alert Terminology
    - Call Contracts: The right to buy shares as indicated in the contract.
    - Put Contracts: The right to sell shares as indicated in the contract.
    - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it.
    - Premium/Option Price: The price of the contract.

    For more information, visit our Guide to Understanding Options Alerts or read more news on unusual options activity.

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ABBV alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABBV
    $AMGN
    $ANNX
    $ASRT

    CompanyDatePrice TargetRatingAnalyst
    Eli Lilly and Company
    $LLY
    2/20/2026$1350.00Overweight
    Barclays
    Bristol-Myers Squibb Company
    $BMY
    2/20/2026$75.00Overweight
    Barclays
    Amgen Inc.
    $AMGN
    2/20/2026$185.00Equal Weight
    Barclays
    AbbVie Inc.
    $ABBV
    2/20/2026$275.00Overweight
    Barclays
    Amgen Inc.
    $AMGN
    1/20/2026$335.00Outperform → Mkt Perform
    Bernstein
    Hims & Hers Health Inc.
    $HIMS
    1/12/2026$33.00In-line
    Evercore ISI
    AbbVie Inc.
    $ABBV
    1/8/2026Outperform → Peer Perform
    Wolfe Research
    Eli Lilly and Company
    $LLY
    1/7/2026$1250.00Buy
    UBS
    More analyst ratings

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Approval for REPATHA issued to AMGEN INC

    Submission status for AMGEN INC's drug REPATHA (SUPPL-44) with active ingredient EVOLOCUMAB has changed to 'Approval' on 11/20/2024. Application Category: BLA, Application Number: 125522, Application Classification:

    11/21/24 12:43:07 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    October 18, 2024 - FDA Roundup: October 18, 2024

    For Immediate Release: October 18, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  This week, FDA continues ongoing efforts to increase access and supply of IV and peritoneal dialysis (PD) fluids following Hurricane Helene-related damage to Baxter International Inc.’s facility in Marion, North Carolina. Specifically, FDA acted quickly to c

    10/18/24 4:16:25 PM ET
    $NVCR
    $BAX
    Medical/Dental Instruments
    Health Care

    FDA Approval for VYALEV issued to ABBVIE INC

    Submission status for ABBVIE INC's drug VYALEV (ORIG-1) with active ingredient FOSCARBIDOPA AND FOSLEVODOPA has changed to 'Approval' on 10/16/2024. Application Category: NDA, Application Number: 216962, Application Classification: Type 3 - New Dosage Form and Type 4 - New Combination

    10/18/24 4:38:13 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    VP, Finance & CAO Busch Matthew C. sold $375,790 worth of shares (1,000 units at $375.79), decreasing direct ownership by 23% to 3,423 units (SEC Form 4)

    4 - AMGEN INC (0000318154) (Issuer)

    2/20/26 7:43:21 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    EVP, R&D and CSO Thakkar Roopal was granted 18,137 shares, increasing direct ownership by 43% to 60,413 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:36:48 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, CHIEF COMMERCIAL OFFICER Stewart Jeffrey Ryan was granted 53,749 shares, increasing direct ownership by 101% to 106,983 units (SEC Form 4)

    4 - AbbVie Inc. (0001551152) (Issuer)

    2/20/26 6:35:24 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP and President, Aetna Nelson Steven H bought $1,289 worth of shares (24 units at $53.70) (SEC Form 4)

    4 - CVS HEALTH Corp (0000064803) (Issuer)

    1/27/26 5:20:15 PM ET
    $CVS
    Retail-Drug Stores and Proprietary Stores
    Consumer Staples

    Director Carson William H. bought $20,657 worth of shares (4,115 units at $5.02), increasing direct ownership by 8% to 54,405 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    1/2/26 4:30:06 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Carson William H. bought $18,394 worth of shares (4,115 units at $4.47), increasing direct ownership by 9% to 50,290 units (SEC Form 4)

    4 - Annexon, Inc. (0001528115) (Issuer)

    12/3/25 4:30:14 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    SEC Filings

    View All

    SEC Form 10-K filed by AbbVie Inc.

    10-K - AbbVie Inc. (0001551152) (Filer)

    2/20/26 2:38:42 PM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-K filed by Travere Therapeutics Inc.

    10-K - Travere Therapeutics, Inc. (0001438533) (Filer)

    2/19/26 4:47:50 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 8-K filed by Amgen Inc.

    8-K - AMGEN INC (0000318154) (Filer)

    2/19/26 4:27:56 PM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Barclays initiated coverage on Eli Lilly with a new price target

    Barclays initiated coverage of Eli Lilly with a rating of Overweight and set a new price target of $1,350.00

    2/20/26 8:24:27 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Bristol-Myers with a new price target

    Barclays initiated coverage of Bristol-Myers with a rating of Overweight and set a new price target of $75.00

    2/20/26 8:24:06 AM ET
    $BMY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Amgen with a new price target

    Barclays initiated coverage of Amgen with a rating of Equal Weight and set a new price target of $185.00

    2/20/26 8:23:35 AM ET
    $AMGN
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

    First all-oral, fixed-duration combination regimen approved for previously untreated patients with CLL Approval supported by data from the Phase 3 AMPLIFY trialRegimen offers another option for the potential of time off treatment, marking a meaningful advance in long-term disease managementNORTH CHICAGO, Ill., Feb. 20, 2026 /PRNewswire/ -- AbbVie (NYSE:ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental new drug application (sNDA) for the combination regimen of VENCLEXTA® (venetoclax) and acalabrutinib for the treatment of previously untreated adult patients with chronic lymphocytic leukemia (CLL). The approval is supported by data from the Phas

    2/20/26 2:00:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alopecia Areata Market Set to Expand by 2036, Due to the Emergence of Novel Drug Classes Such as OX40L Inhibitors, IL-2 Inhibitors, IL-7Rα, and Others | DelveInsight

    The alopecia areata market is expected to grow significantly as awareness of the condition increases, potentially expanding further in the coming years, supported by rising prevalence. Additionally, the launch of emerging therapies such as RINVOQ (AbbVie), Bempikibart (Q32 Bio), Coacillium (Legacy Healthcare), ALM 223 (Almirall), Amlitelimab (Sanofi), HCW9302 (HCW Biologics), ALY-101 (ALYS Pharmaceuticals), DR-01 (Dren Bio), Rezpegaldesleukin (Nektar Therapeutics), and others will further propel the market growth.LAS VEGAS, Feb. 19, 2026 /PRNewswire/ -- Recently published Alopecia Areata Market Insights report includes a comprehensive understanding of current treatment practices, alopecia ar

    2/19/26 5:31:00 PM ET
    $ABBV
    $HCWB
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Commercial Physical & Biological Resarch

    Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

    U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.

    2/19/26 4:01:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    Leadership Updates

    Live Leadership Updates

    View All

    Hims & Hers Announces Agreement to Acquire Eucalyptus, Accelerating Its Vision to Become the Leading Global Consumer Health Platform

    Eucalyptus is a consumer healthcare leader in Australia, the UK and Germany, with expanding new operations in Japan and Canada. Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced it has entered into a definitive agreement to acquire Eucalyptus, an international leader in digital health, accelerating the company's ability to bring access to high-quality, personalized care to more people across the world. As its US business continues to grow, Hims & Hers will be well-positioned, upon closing of the acquisition, to expand into Australia and Japan and deepen its presence in the UK, Germany, and Canada. The terms of the transaction have been structu

    2/19/26 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    Lilly to acquire Orna Therapeutics to advance cell therapies

    Orna's in vivo CAR-T pipeline includes potential best-in-class programs to reset the immune system and address B cell-driven autoimmune diseases Acquisition provides a broad platform for long-term innovation in genetic medicine and in vivo cell engineering INDIANAPOLIS and WATERTOWN, Mass., Feb. 9, 2026 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Orna Therapeutics, Inc., a biotechnology company dedicated to engineering immune cells in vivo, today announced entry into a definitive agreement for Lilly to acquire Orna. Orna is advancing a new class of therapeutics utilizing engineered circular RNA paired with novel lipid nanoparticles to allow the patient's own body to generate cell

    2/9/26 7:00:00 AM ET
    $LLY
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Hims & Hers Names Deb Autor as Chief Policy Officer to Lead Global Policy and Regulatory Strategy

    Hims & Hers Health, Inc. (NYSE:HIMS), the leading health and wellness platform, today announced the appointment of Deb Autor as the company's first Chief Policy Officer. In this new role, Autor will collaborate with other stakeholders, including consumers, telehealth platforms, providers, advocacy groups, medical associations, pharmaceutical companies, medtech innovators, policymakers, and regulators, with the goal of paving the way to the healthcare of the future - where the power of technology will be combined with the best of personalized care. She will lead the company's global public policy, regulatory, and government affairs functions. A former senior leader at the FDA, prosecutor f

    11/17/25 6:00:00 AM ET
    $HIMS
    Medical/Nursing Services
    Health Care

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    Financials

    Live finance-specific insights

    View All

    Travere Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results

    U.S. net product sales of FILSPARI reached $103 million, representing 108% growth compared to prior year period; all-time high 908 new PSFs received during the quarter U.S. net product sales of FILSPARI totaled $322 million for full year 2025; total net product sales were $410 million for full year 2025 PDUFA target action date for FILSPARI in FSGS is April 13, 2026; Company positioned for a successful commercial launch, if approved Enrollment activities have resumed for the pivotal Phase 3 HARMONY Study of pegtibatinase in classical HCU Travere Therapeutics, Inc. (NASDAQ:TVTX) today reported its fourth quarter and full year 2025 financial results and provided a corporate update.

    2/19/26 4:01:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    AbbVie Declares Quarterly Dividend

    NORTH CHICAGO, Ill., Feb. 19, 2026 /PRNewswire/ -- The board of directors of AbbVie Inc. (NYSE:ABBV) today declared a quarterly cash dividend of $1.73 per share.  The cash dividend is payable May 15, 2026, to stockholders of record at the close of business on April 15, 2026.Since the company's inception in 2013, AbbVie has increased its dividend by more than 330 percent. AbbVie is a member of the S&P Dividend Aristocrats Index, which tracks companies that have annually increased their dividend for at least 25 consecutive years.About AbbVieAbbVie's mission is to discover and deliver innovative medicines and solutions that solve serious health issues today and address the medical challenges of

    2/19/26 9:37:00 AM ET
    $ABBV
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Travere Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results

    Travere Therapeutics, Inc. (NASDAQ:TVTX) today announced it will report fourth quarter and full year 2025 financial results on Thursday, February 19, 2026, after the close of the U.S. financial markets. The Company will host a conference call and webcast to discuss the financial results and provide a general business update at 4:30 p.m. ET. The webcast and dial-in information can be accessed on the Investor page of Travere's website at https://ir.travere.com/events-and-presentations. Following the live webcast, an archived version of the call will be available for 30 days on the Company's website. About Travere Therapeutics At Travere Therapeutics, we are in rare for life. We are a bi

    2/12/26 4:30:00 PM ET
    $TVTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 7:21:59 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 6:46:41 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Annexon Inc.

    SC 13G/A - Annexon, Inc. (0001528115) (Subject)

    11/14/24 5:30:27 PM ET
    $ANNX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABBV
    $AMGN
    $ANNX
    $ASRT
    Insider purchases explained

    Analytical look into recent insider purchases

    View All

    Insider Analysis: Purchase at Assertio Holdings Inc. on Jun 6

    Recent insider transactions at Assertio Holdings Inc. have brought attention to the company's stock activity. On June 6, 2024, Mason Heather L purchased $24,250 worth of shares, acquiring 25,000 units at $0.97 per share. This transaction increased Mason Heather L's direct ownership by 13% to 212,650 units, as reported in the SEC Form 4. Several other notable insider transactions have taken place at Assertio Holdings Inc. leading up to this purchase. Patel Ajay, Schwichtenberg Paul, and Schlessinger Sam all converted options into shares and covered exercise/tax liability by utilizing their shares. These transactions resulted in ownership increases of 16%, 20%, and 21%, respectively. Addition

    6/10/24 1:20:50 AM ET
    $ASRT
    Biotechnology: Pharmaceutical Preparations
    Health Care